EGFR and non-small cell lung carcinoma: In patients with advanced non-small cell lung cancer (NSCLC), epidermal growth factor receptor (EGFR) mutations are reportedly a predictive factor for the effect of EGFR tyrosine kinase inhibitors (EGFR-TKIs)1, 2, 3, 4, 5.